Wockhardt to exit US generic pharmaceutical segment
Mumbai: Wockhardt has announced a significant strategic realignment of its U.S. business, marking an exit from the generic pharmaceutical segment in the United States. The exit paves the way for deeper focus and investment in its advanced product portfolio.
The decision follows years of losses in the U.S. generics space, with the business incurring a loss of nearly USD 8 million in FY 2025 alone. After a comprehensive strategic review, Wockhardt determined that the continued operation in this segment would detract from its broader innovation agenda.
Accordingly, Wockhardt has filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its US step down subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC, both incorporated in Delaware which are wholly owned subsidiaries of Wockhardt Bio AG.
"This decision, effective 11 July 2025, enables a clean and structured exit from a legacy segment and unlocks management bandwidth and capital for high-impact areas. By stepping away from the commoditized generics space, Wockhardt is positioning itself to create long-term value through innovation, scientific excellence, and sustainable profitability," Wockhardt stated.
This strategic reset aligns with Wockhardt’s focus on building a future-ready business anchored in two key pillars:
1. New Antibiotic Drug Discovery – where Wockhardt has established a leadership position globally, with a strong pipeline of differentiated assets.
2. Biologicals Portfolio in Insulin – leveraging advanced technologies to address critical unmet needs in diabetes care.
Wockhardt reaffirmed its commitment to its pharmaceutical operations in India, the UK, Ireland, and other geographies where its businesses continue to deliver strong performance.
